Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice

Nutrition and Metabolism

Volumn 11, Issue 1, 2014, Pages

  Zhu, Wei ^b   Chen, Sifan ^a,b   Li, Zilun ^c   Zhao, Xiaohong ^c   Li, Wenxue ^b   Sun, Yanshuang ^a   Zhang, Zili ^a   Ling, Wenhua ^a   Feng, Xiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

AMPK; Lipid metabolic disorder; NAFLD; Oxidative stress; Resveratrol; Sirt1

Indexed keywords

GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE SENSITIVE LIPASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MESSENGER RNA; P47PHOX PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RESVERATROL; SIRTUIN 1; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; FATTY LIVER; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING;

MUS;

EID: 84908073362     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-11-35     Document Type: Article

References (38)

1. Nonalcoholic fatty liver disease. Angulo P, N Engl J Med 2002 346 1221 1231
2. Human fatty liver disease: old questions and new insights. Cohen JC, Horton JD, Hobbs HH, Science 2011 332 1519 1523
3. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ, J Clin Invest 2005 115 1343 1351
4. Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. Reid BN, Ables GP, Otlivanchik OA, Schoiswohl G, Zechner R, Blaner WS, Goldberg IJ, Schwabe RF, Chua SC Jr, Huang LS, J Biol Chem 2008 283 13087 13099
5. Resveratrol: from grapevines to mammalian biology. Pervaiz S, FASEB J 2003 17 1975 1985
6. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das DK, Maulik N, Free Radic Biol Med 2007 43 720 729
7. Resveratrol improves health and survival of mice on a high-calorie diet. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA, Nature 2006 444 337 342
8. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Masubuchi Y, Sugiyama S, Horie T, Chem Biol Interact 2009 179 273 279
9. Sirt1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, Zhai Q, Cell Metab 2007 6 307 319
10. AMP-activated protein kinase signaling in metabolic regulation. Long YC, Zierath JR, J Clin Invest 2006 116 1776 1783
11. Chronic AMP-activated protein kinase activation and a high-fat diet have an additive effect on mitochondria in rat skeletal muscle. Fillmore N, Jacobs DL, Mills DB, Winder WW, Hancock CR, J Appl Physiol 2010 109 511 520
12. + metabolism and Sirt1 activity. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J, Nature 2009 458 1056 1060
13. Sirt1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. Lan F, Cacicedo JM, Ruderman N, Ido Y, J Biol Chem 2008 283 27628 27635
14. Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Castle CK, Colca JR, Melchior GW, Arterioscler Thromb 1993 13 302 309
15. Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Chen S, Li J, Zhang Z, Li W, Sun Y, Zhang Q, Feng X, Zhu W, Can J Physiol Pharmacol 2012 90 237 242
16. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J, Cell 2006 127 1109 1122
17. Suppressive effects of hydroxytyrosol on oxidative stress and nuclear Factor-kappaB activation in THP-1 cells. Zhang X, Cao J, Jiang L, Zhong L, Biol Pharm Bull 2009 32 578 582
18. Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes. Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Sumino H, Morimoto S, Kanda T, J Int Med Res 2006 34 297 302
19. Resveratrol addiction: to die or not to die. Shakibaei M, Harikumar KB, Aggarwal BB, Mol Nutr Food Res 2009 53 115 128
20. The ins and outs of mitochondrial dysfunction in NASH. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D, Diabetes Metab 2004 30 121 138
21. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K, J Hepatol 2002 37 56 62
22. Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Aronis A, Madar Z, Tirosh O, Free Radic Biol Med 2005 38 1221 1230
23. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL, Hypertension 2004 43 48 56
24. Insulin signalling and the regulation of glucose and lipid metabolism. Saltiel AR, Kahn CR, Nature 2001 414 799 806
25. Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Yen GC, Duh PD, Lin CW, Free Radic Res 2003 37 509 514
26. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefler G, Zechner R, Science 2006 312 734 737
27. Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Turpin SM, Hoy AJ, Brown RD, Rudaz CG, Honeyman J, Matzaris M, Watt MJ, Diabetologia 2011 54 146 156
28. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA, Nature 2003 425 191 196
29. Resveratrol is not a direct activator of SIRT1 enzyme activity. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M, Chem Biol Drug Des 2009 74 619 624
30. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE ESY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA, Science 2013 339 1216 1219
31. Hypothalamic Sirt1 regulates food intake in a rodent model system. Cakir I, Perello M, Lansari O, Messier NJ, Vaslet CA, Nillni EA, PLoS One 2009 4 8322
32. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. de Kreutzenberg SV, Ceolotto G, Papparella I, Bortoluzzi A, Semplicini A, Dalla Man C, Cobelli C, Fadini GP, Avogaro A, Diabetes 2010 59 1006 1015
33. FoxO proteins in insulin action and metabolism. Barthel A, Schmoll D, Unterman TG, Trends Endocrinol Metab 2005 16 183 189
34. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. Plas DR, Thompson CB, J Biol Chem 2003 278 12361 12366
35. Active and inactive protein kinases: structural basis for regulation. Johnson LN, Noble ME, Owen DJ, Cell 1996 85 149 158
36. AMP-activated protein kinase: role in metabolism and therapeutic implications. Schimmack G, Defronzo RA, Musi N, Diabetes Obes Metab 2006 8 591 602
37. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Ruderman N, Prentki M, Nat Rev Drug Discov 2004 3 340 351
38. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH, Cell 2012 148 421 433